Real-world clinical outcomes of cabozantinib as a second-line treatment for advanced hepatocellular carcinoma: a retrospective US claims analysis
Cabozantinib shows consistent effectiveness and safety in the 2L HCC setting following prior TKIs or IO-based regimens in real-world clinical practice. These findings may inform 2L treatment decisions.
Authors
- Xiaoyu Nie (ORCID: https://orcid.org/0000-0003-3408-1630)
- Michael Locker
- Daniel H. Ahn (ORCID: https://orcid.org/0000-0002-0161-4018)
- Noh Jin Park
- Travis Wang (ORCID: https://orcid.org/0000-0002-1175-1884)
- Shengsheng Yu (ORCID: https://orcid.org/0000-0002-1630-8224)
- Zheng‐Yi Zhou (ORCID: https://orcid.org/0000-0001-9014-8479)
Institutions
- Exelixis (United States) (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-08-09
- DOI
- https://doi.org/10.1093/oncolo/oyaf252
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.64
Funders
- Exelixis
- European Society for Medical Oncology